⏳ Fetching live dividend data...
Home › Calculator › KSPHF Dividend Calculator 2026
Kissei Pharmaceutical Co., Ltd. · OTC
Price: $25.77 · Annual div: $0.77/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in KSPHF → $11.76M in 10 years · $6,042.32/month
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. Its products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was incorporated in 1946 and is headquartered in Matsumoto, Japan.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime.
Ready to invest? Open KSPHF position with:
Real after-tax yield depends on where you live and how you hold KSPHF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.99% | 0.19% | $299 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.54% | -0.26% | $254 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.39% | -0.41% | $239 / yr |
| 🇬🇧 UK ISA | 0% | 2.99% | 0.19% | $299 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.73% | -0.07% | $273 / yr |
| 🇨🇦 TFSA | 0% | 2.99% | 0.19% | $299 / yr |
| 🇨🇦 CA Taxable | 25% | 2.24% | -0.56% | $224 / yr |
| 🇦🇺 Super (pension) | 15% | 2.54% | -0.26% | $254 / yr |
| 🇦🇺 AU Taxable | 30% | 2.09% | -0.71% | $209 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.20% | -0.60% | $220 / yr |
| 🇫🇷 FR Taxable | 30% | 2.09% | -0.71% | $209 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.77/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
KSPHF pays quarterly — 4 times per year. Next ex-div: TBD.
How KSPHF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for KSPHF sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the KSPHF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →